InMode Ltd. (NASDAQ:INMD) Holdings Raised by Jump Financial LLC

Jump Financial LLC grew its stake in shares of InMode Ltd. (NASDAQ:INMD) by 12.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,921 shares of the healthcare company’s stock after acquiring an additional 5,931 shares during the period. Jump Financial LLC owned 0.08% of InMode worth $917,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in InMode in the fourth quarter valued at about $87,000. Farther Finance Advisors LLC grew its stake in shares of InMode by 26.2% in the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock valued at $93,000 after buying an additional 1,154 shares in the last quarter. Covestor Ltd increased its holdings in InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company’s stock worth $99,000 after buying an additional 723 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in InMode during the fourth quarter valued at approximately $114,000. Finally, Sterling Capital Management LLC lifted its stake in InMode by 23.5% in the fourth quarter. Sterling Capital Management LLC now owns 9,162 shares of the healthcare company’s stock valued at $153,000 after acquiring an additional 1,742 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Price Performance

INMD stock opened at $14.80 on Tuesday. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of 6.30 and a beta of 1.96. The company has a 50-day moving average of $17.60 and a two-hundred day moving average of $17.63. InMode Ltd. has a 52-week low of $13.68 and a 52-week high of $19.85.

Analyst Ratings Changes

Several brokerages have recently commented on INMD. Jefferies Financial Group dropped their price target on shares of InMode from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Monday, April 14th. Barclays raised their target price on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Wednesday, April 9th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, InMode presently has a consensus rating of “Hold” and an average target price of $21.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.